NCT00503685 2018-06-06Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR TherapyEli Lilly and CompanyPhase 2 Completed65 enrolled 14 charts